文献速递特殊人群用药肝肾功能剂量调整

Patritumab Deruxtecan(HER3-DXd)单药治疗实体瘤的整合双分析物群体药代动力学模型

Integrated Two-Analyte Population Pharmacokinetics Model of Patritumab Deruxtecan (HER3-DXd) Monotherapy in Patients with Solid Tumors.
PubMed 文献 · Clin Pharmacokinet · 2025-05-23

本研究基于四项I/II期研究(N=733)的汇总数据,建立整合群体PK模型同时描述抗HER3抗体偶联DXd(anti-HER3-ac-DXd)和游离DXd的处置。模型支持已选的5.6 mg/kg Q3W给药方案,中度肝损伤是DXd暴露的显著协变量,其他预设协变量对暴露无临床重要影响,无需基于这些协变量调整剂量。

要点

  • 整合模型同时刻画抗HER3-ac-DXd和DXd的PK特征
  • 中度肝损伤影响DXd暴露但不影响抗HER3-ac-DXd暴露
  • 其他预设协变量对两种分析物暴露无临床重要影响

核心结论

  • 最终整合群体PK模型表征了HER3-DXd治疗实体瘤患者中抗HER3-ac-DXd和DXd的PK特征,支持已选的5.6 mg/kg Q3W给药方案。
  • 与当前数据一致,基于所研究协变量进行剂量调整是不必要的。

研究设计与样本

  • 汇总四项I/II期研究数据,纳入乳腺癌、肺癌和结直肠癌患者(N=733),接受HER3-Xd单药静脉给药(1.6-8.0 mg/kg,每3周一次)。
  • 采用逐步法建立整合群体PK模型,同时描述抗HER3-ac-DXd和DXd的处置。

主要发现

  • 抗HER3-ac-DXd的PK由二室模型描述,含三条消除途径:线性瞬时清除、非特异性时间依赖性清除和非线性米氏清除。
  • DXd的PK由一室模型描述,含两条清除途径:线性和非线性米氏清除。
  • DXd的生成受抗HER3-ac-DXd全部三条清除途径的速率限制。
  • 中度肝损伤是DXd暴露的显著协变量,但对 anti-HER3-ac-DXd 暴露无显著影响。
  • 其他预设协变量对 anti-HER3-ac-DXd 或 DXd 的暴露无临床重要影响。

临床怎么用

  • 临床使用HER3-Xd 5.6 mg/kg Q3W方案时,无需基于所研究的协变量(含中度肝损伤对DXd暴露的影响)进行剂量调整。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Patritumab deruxtecan (HER3-DXd, also known as MK-1022) is an antibody-drug conjugate comprising a fully human monoclonal antibody against human epidermal growth factor receptor 3 (HER3) attached to a topoisomerase I inhibitor payload, deruxtecan (DXd), via a tetrapeptide-based cleavable linker. We developed a population pharmacokinetic (PK) model for anti-HER3-ac-DXd (anti-HER3 antibody conjugated DXd) and DXd to characterize their PKs and investigate the impact of preselected covariates. METHODS: Data were pooled from four phase I/II studies including patients with breast, lung, and colorectal cancer (N = 733) treated with HER3-DXd monotherapy (1.6-8.0 mg/kg intravenously every 3 weeks). An integrated population PK model, established using stepwise methodology, simultaneously described both anti-HER3-ac-DXd and DXd disposition. RESULTS: Anti-HER3-ac-DXd PK was described by a two-compartment model with three elimination pathways: linear transient clearance, nonspecific time-dependent clearance, and nonlinear Michaelis-Menten clearance. DXd PK was described by a one-compartment model with two clearance pathways: linear and nonlinear Michaelis-Menten clearance. The formation of DXd was rate limited by all three clearance pathways of anti-HER3-ac-DXd. Moderate hepatic impairment was a significant covariate on DXd but not anti-HER3-ac-DXd exposure. Other prespecified covariates did not have a clinically important impact on exposure to anti-HER3-ac-DXd or DXd. CONCLUSIONS: The final integrated population PK model characterized the PK of both anti-HER3-ac-DXd and DXd in patients with solid tumors treated with HER3-DXd and supported the selected 5.6 mg/kg Q3W dosing regimen. Consistent with current data, dose adjustment based on the covariates investigated is not warranted.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Xu Y, Lee M, Joshi R, et al. Integrated Two-Analyte Population Pharmacokinetics Model of Patritumab Deruxtecan (HER3-DXd) Monotherapy in Patients with Solid Tumors. Clin Pharmacokinet. 2025. PMID: 40408047. doi:10.1007/s40262-025-01521-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。